

## Alaska HB 228 Psychedelic Medicine Task Force

### **Public Comment Packet, Part 1:**

### **Comments Received through Monday, April 28, 2025**



Members of the Alaska Task Force for the Regulation of Psychedelic Medicines:

Thank you for your time to consider public comment on your draft report. I am writing on behalf of Compass Pathways, a precommercial biotech company dedicated to accelerating patient access to evidence-based innovation in mental health.

As you know, psychedelic compounds such as psilocybin are currently Schedule I drugs in Alaska. However, pharmaceutical-grade, synthetic formulations of these compounds are currently being studied by pharmaceutical companies like Compass Pathways for the treatment of serious and difficult to treat mental health conditions. For example, Compass is currently studying COMP360, a synthesized, pharmaceutical grade formulation of psilocybin, in phase 3 trials for patients with Treatment Resistant Depression (TRD). Compass is also in process of designing a late-stage clinical program for patients with post-traumatic stress disorder (PTSD).

As you note in your draft report, prompt rescheduling of these compounds after U.S. Food and Drug Administration (FDA) approval and U.S. Drug Enforcement Administration (DEA) rescheduling is paramount to ensuring access for patients in Alaska. To achieve this goal, the task force should recommend that the legislature enact a "trigger" law that would allow for the prompt rescheduling and immediate legal use of psychedelic treatments once they are FDA-approved and DEA-rescheduled. Enacting such a law would allow manufacturers of these products to ship into Alaska, thereby enabling patients to access them through licensed healthcare providers.

We understand that Alaska has a Controlled Substances Advisory Committee who typically makes these sorts of rescheduling recommendations directly to the Governor, who then introduces legislation to fully enact them. However, processes such as these can cause unnecessary delays in access for the patients in Alaska who are in need of potentially new, innovative mental health treatment options. Accordingly, we urge the Task Force to recommend the enactment of a rescheduling trigger law to immediately allow for the use of FDA-approved and DEA-rescheduled psychedelic treatments for Alaskans in need.

Thank you for your work on this important issue. Please feel free to contact us if you have further questions or need additional information.

Sincerely,

**Eric Rasmussen**

Vice President, Government Affairs and  
Public Policy  
Compass Pathways